Overview

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
0
Participant gender:
All
Summary
This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium
Criteria
Inclusion Criteria:

- Patient must be HIV positive with HIV RNA values that are within ranges required by
the study

- Patient must have documented failure of certain antiretroviral therapy

- Patient must be on the same antiretroviral therapy for at least the past two months

Exclusion Criteria:

- Patient less than 16 years old

- Additional study criteria will be discussed and identified by the study doctor